In last trading session, Neogenomics Inc (NASDAQ:NEO) saw 0.59 million shares changing hands with its beta currently measuring 1.23. Company’s recent per share price level of $14.30 trading at -$0.5 or -3.38% at ring of the bell on the day assigns it a market valuation of $1.84B. That closing price of NEO’s stock is at a discount of -33.64% from its 52-week high price of $19.11 and is indicating a premium of 15.24% from its 52-week low price of $12.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 891.01K if we extend that period to 3-months.
For Neogenomics Inc (NEO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.03 in the current quarter.
Neogenomics Inc (NASDAQ:NEO) trade information
Upright in the red during last session for losing -3.38%, in the last five days NEO remained trading in the red while hitting it’s week-highest on Tuesday, 01/28/25 when the stock touched $14.30 price level, adding 6.66% to its value on the day. Neogenomics Inc’s shares saw a change of -13.23% in year-to-date performance and have moved -3.77% in past 5-day. Neogenomics Inc (NASDAQ:NEO) showed a performance of -15.48% in past 30-days. Number of shares sold short was 3.55 million shares which calculate 3.08 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 18 to the stock, which implies a rise of 20.56% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would drop -25.87% in reaching the projected high whereas dropping to the targeted low would mean a loss of -25.87% for stock’s current value.
Neogenomics Inc (NEO) estimates and forecasts
Statistics highlight that Neogenomics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -19.35% of value to its shares in past 6 months, showing an annual growth rate of 175.00% while that of industry is 16.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 11.89% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 173.4M for the same. And 10 analysts are in estimates of company making revenue of 172.62M in the next quarter. Company posted 155.55M and 156.24M of sales in current and next quarters respectively a year earlier.
Neogenomics Inc (NASDAQ:NEO)’s Major holders
Insiders are in possession of 1.21% of company’s total shares while institution are holding 99.49 percent of that, with stock having share float percentage of 100.70%. Investors also watch the number of corporate investors in a company very closely, which is 99.49% institutions for Neogenomics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at NEO for having 19.67 million shares of worth $272.82 million. And as of 2024-06-30, it was holding 15.5612 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 14.12 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.1716 of outstanding shares, having a total worth of $195.87 million.
On the other hand, iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 8.28 shares of worth $118.4 million or 6.45% of the total outstanding shares. The later fund manager was in possession of 4.0 shares on Sep 30, 2024 , making its stake of worth around $57.18 million in the company or a holder of 3.11% of company’s stock.
